What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Internal medicine
Jochen Utikal focuses on Melanoma, Immunology, Cancer, Internal medicine and Cancer research.
His research integrates issues of Nivolumab, Ipilimumab, Antibody and Progression-free survival in his study of Melanoma.
The concepts of his Immunology study are interwoven with issues in Embryonic stem cell, Stem cell, Cell biology and Induced stem cells.
His research in Internal medicine intersects with topics in Gastroenterology, Surgery and Oncology.
His study focuses on the intersection of Surgery and fields such as Trametinib with connections in the field of Hazard ratio.
His Cancer research study combines topics in areas such as ErbB, Growth factor receptor and Immune system, Immunotherapy.
His most cited work include:
- Directly Reprogrammed Fibroblasts Show Global Epigenetic Remodeling and Widespread Tissue Contribution (1589 citations)
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma (1574 citations)
- Induced pluripotent stem cells generated without viral integration (1553 citations)
What are the main themes of his work throughout his whole career to date?
Jochen Utikal mostly deals with Melanoma, Cancer research, Internal medicine, Oncology and Cancer.
His Melanoma research is multidisciplinary, relying on both Targeted therapy, Skin cancer, Immunology and Immunotherapy.
He has researched Immunology in several fields, including Cellular differentiation, Induced pluripotent stem cell and Cell biology.
His biological study spans a wide range of topics, including Tumor microenvironment, Immune system, Carcinogenesis, Myeloid-derived Suppressor Cell and Tumor progression.
His Internal medicine research incorporates elements of Gastroenterology and Surgery.
His work carried out in the field of Oncology brings together such families of science as Metastatic melanoma, Chemotherapy, Phases of clinical research, Dabrafenib and Trametinib.
He most often published in these fields:
- Melanoma (68.36%)
- Cancer research (51.45%)
- Internal medicine (31.16%)
What were the highlights of his more recent work (between 2019-2021)?
- Cancer research (51.45%)
- Melanoma (68.36%)
- Skin cancer (19.32%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Cancer research, Melanoma, Skin cancer, Cancer and Artificial intelligence.
His Cancer research research is multidisciplinary, incorporating elements of Cancer cell, Metastasis, Myeloid-derived Suppressor Cell, Tumor progression and Immunotherapy.
His Cancer cell research is multidisciplinary, incorporating perspectives in Phenotype, Genetic heterogeneity, Reprogramming, SOX2 and Induced pluripotent stem cell.
His Melanoma study incorporates themes from Oncology, Tumor microenvironment, CD8, Immune system and Targeted therapy.
The Skin cancer study combines topics in areas such as Histone methyltransferase, Vemurafenib, Transcriptome, Merkel cell carcinoma and Applications of artificial intelligence.
His studies in Artificial intelligence integrate themes in fields like Nevus and Pattern recognition.
Between 2019 and 2021, his most popular works were:
- An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. (59 citations)
- SOX2 in development and cancer biology. (33 citations)
- SOX2 in development and cancer biology. (33 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
Cancer research, Melanoma, Immune system, Cancer and Tumor microenvironment are his primary areas of study.
His Cancer research research integrates issues from T cell, Targeted therapy, Metastasis and Immunotherapy.
His Immunotherapy research includes themes of Immunosuppression and Oncolytic virus.
Jochen Utikal applies his multidisciplinary studies on Melanoma and Protein kinase A in his research.
Immune system is a subfield of Immunology that Jochen Utikal explores.
His studies deal with areas such as SOX2, Embryonic stem cell and Adult stem cell as well as Cancer.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
